Home / Stocks / Ind Swift Laboratories Lt
INDSWFTLAB

Ind Swift Laboratories Lt Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹330.2

Change

-6.55 (-1.95%)

Open

₹335.75

Prev. Close

₹336.75

Day High

₹336.5

Day Low

₹326.35

Volume Analysis

Traded

273,520

Delivered

137,699

Delivery %

50.34%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (2)

  • •Low return on equity (4.02%)
  • •Below-average fundamentals quality score (49/100)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹345.84 ₹341.17 ₹335.69 ₹331.02 ₹325.54 ₹320.87 ₹315.39
Fibonacci ₹341.17 ₹337.29 ₹334.9 ₹331.02 ₹327.14 ₹324.75 ₹320.87
Camarilla ₹332.99 ₹332.06 ₹331.13 ₹331.02 ₹329.27 ₹328.34 ₹327.41

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+264.9%

1 Week

-8.37%

1 Month

-3.59%

3 Months

+0.19%

6 Months

+150.55%

1 Year

+246.52%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹137.88

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

4.96%

Net margin 11.16% × asset turnover 0.37x × equity multiplier 1.2x

Company Overview

Sector

Healthcare

Market Cap

₹2,881 Cr

P/E (TTM)

31.4

ROE

4.02%

Book Value

₹170.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Ind Swift Laboratories Lt scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (4.02%); below-average fundamentals quality score (49/100). FII holding has been rising.

TopFund Score — Fundamentals Quality

49/100 — Weak

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

0

Valuation

42

Cash Flow

0

Corporate Governance

66

Momentum

72

Institutional Ownership

39

Business Quality

49

Risk & Volatility

74

Liquidity

52

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company is expected to give good quarter
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of -6.14% over past five years.
  • −Company has a low return on equity of 6.74% over last 3 years.
  • −Debtor days have increased from 88.1 to 112 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript for earnings call held on November 04, 2026.

Audio recording of Q2 FY26-27 earnings conference call made available on 4 November 2026.

Investor presentation on un-audited financial results for the quarter ended September 30, 2026

CARE issued Q2FY27 monitoring report for Rs137.20 crore preferential warrants, with no deviation from objects.

CARE final report says Rs 314.60 crore preferential proceeds fully utilized; warrant lapse caused Rs 58.99 crore shortfall.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 290 288 529 33 12 129 138 153 159 151 170 191 240
Expenses + 224 236 437 43 24 135 147 149 151 147 149 158 195
Operating Profit 66 52 91 -10 -12 -7 -9 4 7 4 21 33 45
OPM % 23.0% 18.0% 17.0% -29.0% -99.0% -5.0% -7.0% 2.4% 4.7% 2.8% 12.0% 17.0% 19.0%
Other Income + 7 7 458 11 13 16 220 15 12 22 -3 7 7
Interest 21 21 3 0 0 10 -27 1 2 1 -2 1 1
Depreciation 13 14 20 0 0 6 7 7 7 9 8 8 8
Profit before tax 39 24 527 1 1 -7 230 10 10 16 12 33 43
Tax % 18.0% 19.0% 6.0% -3.0% 31.0% -16.0% 4.0% 17.0% 22.0% 42.0% -26.0% 25.0% 21.0%
Net Profit + 32 19 494 1 0 -5 222 9 8 10 15 25 34
EPS in Rs 5 3 84 0 0 -1 37 1 1 1 2 3 4
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -7 -8 74 -89 -96 -55 -74 360 1,226 17 23 25 52

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 660 653 716 765 757 780 891 1,039 1,207 1,281 574 649 753
Expenses + 571 546 610 631 630 635 709 837 978 1,029 581 602 649
Operating Profit 89 107 106 134 126 144 183 202 229 252 -7 47 104
OPM % 13.0% 16.0% 15.0% 18.0% 17.0% 19.0% 21.0% 19.0% 19.0% 20.0% -1.2% 7.0% 14.0%
Other Income + -31 1 15 16 120 33 23 37 7 434 292 36 33
Interest 117 106 88 28 92 107 100 96 92 51 3 1 0
Depreciation 84 85 88 87 104 90 87 131 57 53 24 31 32
Profit before tax -143 -83 -55 36 50 -20 18 13 87 582 258 51 104
Tax % -17.0% -29.0% -29.0% 39.0% 42.0% 7.0% 117.0% 117.0% 45.0% 28.0% 3.0% 15.0% —
Net Profit + -119 -59 -39 22 29 -21 -3 -2 48 421 250 43 84
EPS in Rs -29 -14 -9 5 6 -4 -1 0 8 71 41 5 10
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth -32 -1 10 7 -1 3 14 17 16 6 -55 13 30

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 553 476 486 507 540 581 544 541 622 872 1,104 1,297 1,387
Borrowings + 1,413 1,457 1,242 1,083 1,148 1,031 1,005 953 862 17 33 18 20
Other Liabilities + 236 240 364 387 188 198 210 247 280 217 232 271 277
Total Liabilities 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,165 1,438 1,673 1,771
Fixed Assets + 1,117 1,099 1,042 934 914 843 753 630 587 8 273 304 314
CWIP 113 78 70 69 20 11 19 10 8 0 0 12 40
Investments 18 18 18 18 19 17 36 29 30 111 213 248 281
Other Assets + 997 1,020 1,007 1,002 972 998 1,011 1,131 1,199 1,047 952 1,110 1,136
Total Assets 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,165 1,438 1,673 1,771
Equity Capital 42 42 45 46 48 60 60 60 60 59 69 87 87

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 98 79 96 73 -64 125 135 150 195 -163 -29 -68
Cash from Investing Activity + -35 -29 -31 -17 -12 -9 -10 5 -13 -104 -113 -69
Cash from Financing Activity + -64 -48 -69 -62 100 -133 -124 -141 -186 699 72 142
Net Cash Flow -1 3 -4 -6 23 -17 1 14 -4 431 -69 5
Free Cash Flow 59 49 63 52 -79 114 131 137 182 -205 -54 -155
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 111 74 90 54 -51 87 73 74 85 -65 323 -131

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 42.01% → 42.93%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 38.96% 49.72% 55.81% 56.41% 56.61% 55.08% 53.88% 45.02% 45.5% 43.14% 46.19% 46.09%
Promoters 42.01% 42.01% 42.01% 42.01% 42.01% 40.94% 40.94% 39.49% 39.49% 43.0% 42.93% 42.93%
FII 0.31% 0.26% 1.27% 0.65% 0.46% 3.07% 4.27% 14.8% 14.33% 13.88% 10.7% 10.78%
DII 18.73% 8.03% 0.94% 0.94% 0.94% 0.91% 0.91% 0.68% 0.68% 0.0% 0.17% 0.2%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Ind Swift Laboratories Lt (this stock) 2,881 31.4 1.95 4.02%
Hikal Limited 2,690 37.8 2.28 2.21%
Advanced Enzyme Tech Ltd 3,102 19.1 1.9 10.5%
Fredun Pharmaceuticals L 2,548 48.1 7.59 15.6%
Solara Active Pha Sci Ltd 3,347 70.7 2.33 -0.13%
Sakar Healthcare Limited 2,319 54.1 6.68 9.99%
Unichem Laboratories Ltd 3,511 29.5 1.26 3.17%

Which Mutual Funds Hold Ind Swift Laboratories Lt?

Frequently Asked Questions about Ind Swift Laboratories Lt

Community Sentiment

What are other investors saying about Ind Swift Laboratories Lt?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.